Healthcare Biopharma Outsourcing Services sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Healthcare Biopharma Outsourcing Services
1.1 - About Healthcare Biopharma Outsourcing Services sector
Companies in Healthcare Biopharma Outsourcing Services provide contract development, clinical operations, and GMP manufacturing across the drug lifecycle. They build compliant manufacturing networks for biologics, cell and gene therapies, and vaccines; deliver aseptic fill‑finish and dosage‑form development; and run preclinical and clinical programs. Strategic buyers in this category enable sponsors to scale capacity, accelerate approvals, and improve supply resilience through integrated, outsourced capabilities.
Common capabilities span end-to-end CDMO manufacturing for biologics, cell and gene therapies and vaccines, including GMP drug substance production, aseptic fill-finish and commercial-scale tech transfer. Providers also offer dosage-form development such as softgels and advanced oral solids, plus analytical and formulation services. On the CRO side, they run GLP toxicology and histopathology, design Phase I–III studies with PK/PD, deliver biometrics and adaptive trial design, and manage regulatory strategy and submissions.
They primarily serve global pharmaceutical manufacturers, emerging biotech innovators, and cell and gene therapy developers. Outcomes include faster time-to-market through integrated development and manufacturing, reduced development risk via robust preclinical and biometrics support, scalable GMP capacity for clinical and commercial supply, and improved regulatory readiness that shortens review cycles and increases approval likelihood.
2. Buyers in the Healthcare Biopharma Outsourcing Services sector
2.1 Top strategic acquirers of Healthcare Biopharma Outsourcing Services companies
Resilience
HQ: United States
Website
- Description: Provider of high-tech, end-to-end biopharmaceutical manufacturing and technology solutions, operating a North-American network that rapidly, safely and at scale produces complex medicines—including gene and cell therapies, vaccines and biologics—while safeguarding supply chains from disruption.
- Key Products:
- End-to-End CDMO Manufacturing Network: Provides GMP-compliant manufacturing for biologics, gene and cell therapies and vaccines through multiple North American sites, giving clients rapid, scalable production and supply resilience
- Fill/Finish Drug Product Services: Delivers vial, syringe and cartridge filling, device assembly and packaging for sterile injectables, securing capacity amid GLP-1 and non-GLP-1 demand surges
- Integrated Digital Data Environment: Implements connected digital systems that centralize reporting, enable near-real-time quality monitoring, streamline communication and accelerate advanced therapy manufacturing timelines
- GMP Capacity Expansion Solutions: Offers scalable large-molecule GMP capacity from its Blue Ash headquarters and other facilities, mitigating supply constraints through 100 % North-American manufacturing.
- Rationale: Provider of GMP CDMO manufacturing network for biologics and cell/gene therapies, sterile injectables fill‑finish, and integrated digital quality environment.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Healthcare Biopharma Outsourcing Services sector
M&A buyer group 1: Medical Device Outsourcing
15 companies
View group →
Description: Companies in this category provide end-to-end outsourced engineering and manufacturing for regulated medical devices. Through Healthcare Medical Device Outsourcing Services, they design, prototype, and produce components and finished devices under ISO 13485 quality systems, integrating supply chain, compliance, and validation support. Their value proposition centers on faster commercialization, lower unit costs, and reliable scalability for OEMs and innovators needing compliant production without expanding internal footprint.
William Demant
HQ: Denmark
- Type: N/A
- Employees: ●●●●●
- Description: Provider of hearing healthcare solutions that encompass hearing aids, personalised hearing care, diagnostic equipment and related services. Demant leverages technologies such as deep neural networks, artificial intelligence, low-energy audio and advanced battery systems to help people hear better, operating globally across 130 countries with more than 22,000 employees.
- Key Products:
- Hearing Aids: Digital hearing aids under brands Oticon and Bernafon amplify sound, reduce noise and improve speech understanding for individuals with hearing loss across varied environments
- Audiometric Diagnostic Instruments: Interacoustics
- Maico and other systems perform hearing tests, measuring auditory thresholds and middle-ear function to aid professionals in diagnosing hearing impairments accurately
- Bone Anchored Hearing Aids: Oticon Medical devices transmit sound vibrations through bone conduction to the inner ear, offering an alternative solution for patients with conductive or mixed hearing loss
- Personal Communication Devices: EPOS and Phonic Ear headsets deliver high-quality audio and noise-cancellation for clear professional communication and assistive listening in offices, classrooms and other demanding settings
🔒
🔒
🔒
View all 15 companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms in Healthcare Biopharma Outsourcing Services sector
3.1 - Buyout funds in the Healthcare Biopharma Outsourcing Services sector
2.2 - Strategic buyer groups for Healthcare Biopharma Outsourcing Services sector
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Healthcare Biopharma Outsourcing Services companies
4.2 - Public trading comparable groups for Healthcare Biopharma Outsourcing Services sector
Valuation benchmark group 1: Biopharma Research Tools and CDMOs
10 companies
View group →
Description: This public trading comparables group comprises biopharma service providers and tools vendors that enable discovery, development, and manufacturing of biologics and gene therapies. Business models span outsourced CRO/CDMO services and sale of critical bioprocess equipment, consumables, and analytics. They are comparable for valuation because revenues are tied to pipeline progression, cGMP capacity, and recurring supply contracts, with specialized know-how and regulatory compliance differentiating scale and margins.
Lonza Group
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of comprehensive services and products focusing on the discovery, development, and manufacturing of active pharmaceutical ingredients, biologics, and innovative dosage forms for the pharmaceutical, biotech, and consumer health industries to support the commercialization of various therapies, with a strong commitment to sustainability and zero-incident workplace initiatives.
- Key Products:
- Bioscience Products: Tools and technologies for cell culture, research, and quality control in biomanufacturing
- Capsule Manufacturing: Pharmaceutical services ensuring high-quality capsule products using gelatin, HPMC, or pullulan
- Biologics Manufacturing: Custom development and manufacturing services for biologics from late phase drug discovery to market supply
- API Development: Early phase discovery and manufacturing of active pharmaceutical ingredients for various therapeutic areas
- Healthcare Solutions: Innovative dosage forms and customized solutions for the pharma and consumer health industries.
🔒
🔒
🔒
View all 10 companies in this group
Request Free Trial Now →
🔒
Revenue growth
Median
15.7%
2025E
16.0%
2026E
EBITDA margin
Median
28.2%
2025E
28.6%
2026E
Cash EBITDA margin
Median
27.6%
2025E
28.0%
2026E
EV/Revenue
Median
8.4x
2025E
6.8x
2026E
EV/EBITDA
Median
28.9x
2025E
24.4x
2026E
EV/Cash EBITDA
Median
29.0x
2025E
25.5x
2026E
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →